

SANTE PHARMACEUTICALS D6

From: SANTE PHARMACEUTICALS D6
Subject: FW: Comments on Annex 15

From: Kathleen Cussen
Sent: Tuesday, June 10, 2014 11:56 AM
To: ADM-GMDP@ema.europa.eu; SANCO PHARMACEUTICALS D6
Subject: Comments on Annex 15

Hi,

Apologies for missing the deadline of May 31st.

Comments on the update to Annex 15 include the following:

Section 5.1 states that the material in scope should be transported in accordance with the conditions defined (i) in the Marketing Authorisation, (ii) product specification file or (iii) by the manufacturer. This conflicts with the current GDP requirement that states that the required storage conditions for medicinal products should be maintained during transportation within the defined limits as described by the manufacturers or on the outer packaging. Regulators have recently consistently emphasised the labelled storage conditions and have ultimately disregarded extended limits that may be included in the products' Marketing Authorisations.

Section 5.4 states that continuous monitoring of critical environmental conditions should be performed due to the variable conditions that may be expected during transport. This seems to conflict with recent expectations that the product's storage conditions should be monitored where monitoring is required. It is also considered unnecessary to monitor ambient conditions if an appropriately qualified active transport system is being used, particularly when continuous temperature monitoring of the product's storage conditions is being performed.

Section 9.8 states that where a worst case product approach is taken that the choice of worst cases should consider toxicity and PDE. PDE is a toxicological assessment, so why both?

Regards,
Kathleen Cussen
Gilead Sciences Ltd.

DISCLAIMER

If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful.

E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment.

Gilead Sciences Limited • Registered as a limited company in Ireland • Registered number 259755
Registered office: Gilead Sciences Limited • IDA Business & Technology Park • Carrigtohill • Co Cork • Ireland • Telephone:
+353 21 4825500 • Fax: +353 21 4825518
